11741 Results

People

  1. Vickers
    Vickers
  2. Offit
    Offit
  3. Robson
    Robson
  4. Horwitz
    Horwitz
  5. Kingham
    Kingham
  6. Panageas
    Panageas
  7. Breitbart
    Breitbart
  8. Halpern
    Halpern
  9. Jarnagin
    Jarnagin
  10. Nelson
    Nelson

Groups

  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)
  7. Psychiatry and Behavioral Sciences, Department of (2780)
  8. Biostatistics Service (2339)
  9. GSK Faculty (2009)
  10. Health Outcomes Research Group (1948)
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (7144)
  2. Meeting Abstract (3307)
  3. Book Section (330)
  4. Review (289)
  5. Editorial (253)
  6. Research Letter (116)
  7. Correspondence (111)
  8. Conference Paper (67)
  9. Guidelines (59)
  10. Miscellaneous (41)
  11. Book Whole (24)
Groups
  1. Population Sciences Research Program (11741)
  2. Survivorship Research (5670)
  3. Department of Medicine (5135)
  4. Epidemiology and Biostatistics (4867)
  5. Solid Tumor Oncology Division (3334)
  6. Surgery (2966)

More Groups

People
  1. Andrew Vickers (880)
  2. Kenneth Offit (788)
  3. Mark Robson (676)
  4. Steven Horwitz (645)
  5. T Peter Kingham (609)
  6. Katherine Panageas (512)

More People

Years
  1. 2025 (236)
  2. 2024 (722)
  3. 2023 (821)
  4. 2022 (828)
  5. 2021 (786)
  6. 2020 (738)

More Years

Publications
  1. Journal of Clinical Oncology (1246)
  2. Blood (374)
  3. Psycho-Oncology (347)
  4. Cancer (240)
  5. Cancer Research (234)
  6. Annals of Surgical Oncology (233)

More Publications

Publishers
  1. American Society of Clinical Oncology (1412)
  2. Elsevier Inc. (1128)
  3. Springer (1112)
  4. Elsevier Science, Inc. (816)
  5. Oxford University Press (753)
  6. Wiley Blackwell (614)

More Publishers

Results (11741)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A simple geriatric vulnerability index for older patients undergoing allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Jakubowski, A. A.; Shahrokni, A.; Dahi, P. B.; Perales, M. A.; Tamari, R.; Shaffer, B. C.; Sauter, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Homebound autologous hematopoietic cell transplantation for plasma cell disorders in an urban setting is safe for patients and preferred by patients and caregivers
    Meeting Abstract

    Landau, H. J.; Shah, G. L.; Reeds, M.; Hilden, P.; Andrejko, M.; Applebaum, A.; Batalha, J.; Cazeau, N.; Chung, D. J.; Cortes, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Superior clinical benefit of brentuximab vedotin in mycosis fungoides versus physician's choice irrespective of CD30 level or large cell transformation status in the phase 3 ALCANZA study
    Meeting Abstract

    Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Bechter, O.; Sanches, J. A.; Stadler, R.; Scarisbrick, J.; Quaglino, P.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Muscle depletion is an important and clinically relevant predictor of outcomes after autologous hematopoietic cell transplantation
    Meeting Abstract

    Iukuridze, A.; Xiao, M.; Brandyn, L.; Teh, J. B.; Mascarenhas, K.; Xu, S.; Rosen, N.; McCune, J. S.; Zain, J. M.; Chen, R. W.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The ECHELON-2 trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas
    Meeting Abstract

    Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Fanale, M. A.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase 1 study of ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Hamadani, M.; Collins, G. P.; Samaniego, F.; Spira, A. I.; Davies, A.; Radford, J.; Caimi, P.; Menne, T.; Boni, J.; Cruz, H.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Activating mutations in CSF1R and additional receptor tyrosine kinases in sporadic and familial histiocytic neoplasms
    Meeting Abstract

    Durham, B. H.; Lopez-Rodrigo, E.; Abramson, D. H.; Picarsic, J.; Pastore, A.; Mandelker, D.; Walsh, M. F.; Arcila, M. E.; Ladanyi, M.; Solit, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • ADCT-301 (camidanlumab tesirine), a novel pyrrolobenzodiaze-based CD25-targeting antibody drug conjugate, in a phase 1 study of replased/refractory non-Hodgkin lymphoma shows activity in T-cell lymphoma
    Meeting Abstract

    Collins, G. P.; Horwitz, S. M.; Davies, A.; Karnad, A.; Samaniego, F.; Spira, A. I.; Fields, P. A.; Menne, T.; Boni, J.; Cruz, H.; more...
    Blood (2018)

    Fulltext@MSK | Save